The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples

The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples

Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western adults. It was suggested that transcripts from a reciprocal trans-splicing event between YPEL5 and PPP1CB were present exclusively in CLL patients (more than 90%). Here we show that the YPEL5–PPP1CB fusion is not specific fo...

Full description

Bibliographic Details
Main Authors: Karl Vandepoele, Jan Philippé, Barbara Denys
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Leukemia Research Reports
Subjects:
Chronic lymphocytic leukemia
YPEL5–PPP1CB
Trans-splicing
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048914200239
id doaj-2aaeeb72f1ab4895aac36a2581ccd197
record_format Article
spelling doaj-2aaeeb72f1ab4895aac36a2581ccd1972020-11-24T22:49:13ZengElsevierLeukemia Research Reports2213-04892015-01-0142515410.1016/j.lrr.2015.07.001The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samplesKarl Vandepoele0Jan Philippé1Barbara Denys2Laboratory for Molecular Diagnostics-Hematology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, 9000 Ghent, BelgiumLaboratory for Molecular Diagnostics-Hematology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumChronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western adults. It was suggested that transcripts from a reciprocal trans-splicing event between YPEL5 and PPP1CB were present exclusively in CLL patients (more than 90%). Here we show that the YPEL5–PPP1CB fusion is not specific for CLL but is also detected in other hematological malignancies such as chronic myeloid leukemia, monoclonal B cell lymphocytosis or acute leukemia and also in normal samples. As such, it is unlikely that the YPEL5–PPP1CB fusion is a good drug target in CLL or a suitable target to monitor disease.http://www.sciencedirect.com/science/article/pii/S2213048914200239Chronic lymphocytic leukemiaYPEL5–PPP1CBTrans-splicing
collection DOAJ
language English
format Article
sources DOAJ
author Karl Vandepoele
Jan Philippé
Barbara Denys
spellingShingle Karl Vandepoele
Jan Philippé
Barbara Denys
The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples
Leukemia Research Reports
Chronic lymphocytic leukemia
YPEL5–PPP1CB
Trans-splicing
author_facet Karl Vandepoele
Jan Philippé
Barbara Denys
author_sort Karl Vandepoele
title The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples
title_short The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples
title_full The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples
title_fullStr The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples
title_full_unstemmed The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples
title_sort ypel5–ppp1cb fusion transcript is detected in different hematological malignancies and in normal samples
publisher Elsevier
series Leukemia Research Reports
issn 2213-0489
publishDate 2015-01-01
description Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western adults. It was suggested that transcripts from a reciprocal trans-splicing event between YPEL5 and PPP1CB were present exclusively in CLL patients (more than 90%). Here we show that the YPEL5–PPP1CB fusion is not specific for CLL but is also detected in other hematological malignancies such as chronic myeloid leukemia, monoclonal B cell lymphocytosis or acute leukemia and also in normal samples. As such, it is unlikely that the YPEL5–PPP1CB fusion is a good drug target in CLL or a suitable target to monitor disease.
topic Chronic lymphocytic leukemia
YPEL5–PPP1CB
Trans-splicing
url http://www.sciencedirect.com/science/article/pii/S2213048914200239
work_keys_str_mv AT karlvandepoele theypel5ppp1cbfusiontranscriptisdetectedindifferenthematologicalmalignanciesandinnormalsamples
AT janphilippe theypel5ppp1cbfusiontranscriptisdetectedindifferenthematologicalmalignanciesandinnormalsamples
AT barbaradenys theypel5ppp1cbfusiontranscriptisdetectedindifferenthematologicalmalignanciesandinnormalsamples
AT karlvandepoele ypel5ppp1cbfusiontranscriptisdetectedindifferenthematologicalmalignanciesandinnormalsamples
AT janphilippe ypel5ppp1cbfusiontranscriptisdetectedindifferenthematologicalmalignanciesandinnormalsamples
AT barbaradenys ypel5ppp1cbfusiontranscriptisdetectedindifferenthematologicalmalignanciesandinnormalsamples
_version_ 1725676711977156608

Similar Items